Compared to the PCOS group, the levels of p-Smad3 significantly decreased (P < 0.01), while the levels of Smad7 were dramatically increased (P < 0.01) in the Rha-treated group and the Met-treated group. This evidence concerns the gene DHX9 and polycystic ovary syndrome.